02/11/2026
ATLMed.org recently hosted an exceptional session on prostate cancer biomarkers led by Dr. Bamidele A. Adesunloye, MD, MSc, FACP, Chief of Medical Oncology at City of Hope. His expert talk, "Prostate Cancer Biomarkers: From PSA to Precision Medicine," provided invaluable insights into the progression of prostate cancer diagnostics, shifting from traditional PSA tests to more precise, individualized biomarkers that help in personalized treatment.
Dr. Adesunloye highlighted key topics, including the limitations of PSA, the evolution of biomarker tests like PHI, 4Kscore, and ExoDx, and the future of prostate cancer diagnosis. He discussed how advanced biomarker testing can significantly reduce unnecessary biopsies, guide risk stratification, and improve treatment decision-making.
We thank Dr. Adesunloye and our sponsor, City of Hope, for making this an educational and enriching event for all attendees. Let's continue advancing the conversation around prostate cancer diagnostics and treatment!
Read the full post at www.atlmed.org/category/atlmed-news